比利时 - 荷兰文 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - bicalutamide 50 mg - filmomhulde tablet - 50 mg - bicalutamide 50 mg - bicalutamide

比利时 - 法文 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - bicalutamide 50 mg - comprimé pelliculé - 50 mg - bicalutamide 50 mg - bicalutamide

比利时 - 法文 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - bicalutamide 150 mg - comprimé pelliculé - 150 mg - bicalutamide 150 mg - bicalutamide

比利时 - 荷兰文 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - bicalutamide 50 mg - filmomhulde tablet - 50 mg - bicalutamide 50 mg - bicalutamide

比利时 - 法文 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - bicalutamide 50 mg - comprimé pelliculé - 50 mg - bicalutamide 50 mg - bicalutamide

比利时 - 法文 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - bicalutamide 50 mg - comprimé pelliculé - 50 mg - bicalutamide 50 mg - bicalutamide

美国 - 英文 - NLM (National Library of Medicine)

northstar rxllc - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d 2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies ( 14.2)]. bicalutamide is contraindicated in: hypersensitivity bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet's components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. women bicalutamide has no indication for women, and should not be used in this population. pregnancy bicalutamide can cause fetal harm when administered to a pregnant woman. [see use in specific populations (8.1) ]. risk summary bicalutamide is contraindicated for use in pregnant women because it can cause fetal harm. bicalutamide is not indicated for us

美国 - 英文 - NLM (National Library of Medicine)

remedyrepack inc. - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d 2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: - hypersensitivity bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. - women bicalutamide has no indication for women, and should not be used in this population. - pregnancy bicalutamide can cause fetal harm when administered to a pregnant woman [see us

加拿大 - 法文 - Health Canada

ranbaxy pharmaceuticals canada inc. - bicalutamide - comprimé - 50mg - bicalutamide 50mg - antineoplastic agents

荷兰 - 荷兰文 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

aurobindo pharma b.v. baarnsche dijk 1 3741 ln baarn - bicalutamide 150 mg/stuk - filmomhulde tablet - crospovidon (e 1202) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 1-water ; macrogol 4000 ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat ; povidon k 30 (e 1201) ; titaandioxide (e 171), crospovidon (e 1202) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; lactose 1-water ; macrogol 4000 ; magnesiumstearaat (e 470b) ; natriumlaurilsulfaat (e 487) ; povidon k 30 (e 1201) ; titaandioxide (e 171), - bicalutamide